All News
RheumNow Week in Review – 11 November 2016
Dr Cush reviews highlights from this week on RheumNow.com
Read ArticleThe Long Awaited PRECISION Study
The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.
Read ArticlePfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read ArticleLilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read ArticleJanssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read ArticleAgressive Early Treatment Prevents Rapid Bone Loss in Rheumatoid Arthritis
The International Osteoporosis Foundation has established the Chronic Inflammation and Bone Structure (CIBS) Working Group to address bone loss in rheumatoid arthritis (RA) and the role of biologic therapies. They conclude that early and aggressive treatment with biologic disease-modifying anti-rheumatic drugs will help prevent progressive bone loss in patients with RA.
Read ArticleDo Statins Reduce Cardiovascular Disease in Rheumatoid Arthritis?
RA increases CV risk considerably. But whose responsibility is it to manage CV risk in RA patients?
Read ArticleRheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read ArticleBariatric Surgery Thwarts Gout and Hyperuricemia
The rising incidence of gout has been directly linked to the obesity epidemic. The influence of obesity on gout was further tested in a cohort study of obese patients undergoing bariatric surgery as part of the Swedish Obese Subjects (SOS) study.
Read ArticleACP Gout Guidelines Reviewed and Critiqued by Rheumatologists
ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.
Read ArticleDecreased CD4 T Cells with Rituximab Infusions
Rituximab (RTX) is a monoclonal antibody directed against the CD20 antigen on B cells and when administered causes a marked depletion of CD20+ B cells.
Read ArticleWhen Cheap Generics Morph Into Expensive Prescriptions
The Wall Street Journal has reported an alarming trend in generic drug pricing that affects many, especially the elderly and those with arthrtis.
Read ArticleThe RheumNow Week in Review – 28 October 2016
Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com
Read ArticleSimultaneous Versus Staged Bilateral Total Knee Arthroplasty
This metanalysis from 2013 reports on an important issue for orthopedists and rheumatologists alike. The issue being in those who need bilateral total knee arthroplasty, is it better to do both knees at once or to do one at a time (staged, serial) arthroplasties..
Read ArticlePOSTURE Study: Apremilast Fails in Ankylosing Spondylitis
ClinicalTrials.gov has listed the results of the POSTURE study, a large randomized placebo-controlled trial wherein apremilast was found to yield no benefit (compared to placebo) in treating ankylosing spondylitis (AS) (32.5% vs. 36.6% ASAS20 at week 16) patients.
Read ArticleKawasaki Disease Pathogenesis Hinges on Interleukin-1
Researchers from the Toronto Hospital for Sick Children have published in the Journal of Immunology that a polymorphism in the inositol-triphosphate 3-kinase C (ITPKC) (rs28493229) is associated with the pathogenesis of Kawasaki's disease (KD).
Read ArticleOctober-September 2016 Top Social Media News
Following is a list of top tweets in September and October 2016; they were selected based on the number of clicks, retweets and likes by the viewership. More than 40,000 people were reached with the first one on our list.
Read ArticleEarly Intervention with Corticosteroids and IVIG is Crucial in Kawasaki Disease
The current JAMA Pediatrics issue has published a report showing that adjunctive corticosteroid therapy yielded significantly fewer coronary artery complications compared with intravenous immunoglobulin therapy alone, particularly among high-risk patients with Kawasaki disease.
Read ArticleNor-Switch Study Shows it's Safe to Switch to a Biosimilar
The results of the Nor-Switch study were presented at the United European Gastroenterology annual congress this week demonstrating no significant difference in effect, adverse effects or antibody formation in patients switched from Remicade to the biosimilar infliximab (CT-P13, Remsima).
Read ArticleReview of Herpes Zoster with Immunosuppression and Autoimmune Disease
Researchers from the University of British Columbia reported on their systematic review and meta-analysis of risk of herpes zoster (HZ) in patients receiving biologics, DMARDs and/or corticosteroids for autoimmune diseases.
Read Article